Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: SusieQ1065 who wrote (29040)	11/7/2001 10:03:17 AM
From: ChrisJP	Respond to of 208838

ISSX -- now at 30. Amazing. Chris

To: SusieQ1065 who wrote (29040)	11/7/2001 10:03:57 AM
From: wgh613	Respond to of 208838

MEW news, Quest Diagnostics and Vasogen form strategic alliance to jointly commercialize immune modulation therapy TETERBORO, NJ, and TORONTO, ON, Nov 7, 2001 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX chart, msgs), the leading provider of diagnostic testing, information and services in the U.S., and Vasogen Inc. (TSE: VAS chart, msgs; AMEX: MEW chart, msgs), a developer of immune modulation therapies for the treatment of inflammatory disease, today announced the formation of a strategic alliance to jointly commercialize Vasogen's immune modulation therapy in the United States. Vasogen's immune modulation therapy targets a fundamental cause of a broad range of diseases by beneficially modulating destructive inflammatory processes. Under the terms of the agreement, Quest Diagnostics has been granted the exclusive rights to distribute Vasogen's immune modulation therapy in the United States. As clinical trials of Vasogen's immune modulation therapy advance in the areas of cardiovascular, autoimmune, and other inflammatory diseases, Vasogen and Quest Diagnostics will work together to establish the distribution infrastructure to support a successful market introduction. The companies will share in product revenues. As part of the agreement, Quest Diagnostics will make a $7.5 million (U.S.) equity investment in Vasogen. In addition, Quest Diagnostics' continued exclusivity is subject to milestone payments, the timing of which is tied to the FDA approval process. "Vasogen has developed a therapeutic intervention that targets diseases affecting millions of Americans," said Surya Mohapatra, Ph.D., President and Chief Operating Officer of Quest Diagnostics. "We look forward to collaborating with Vasogen to introduce this innovative new treatment to the U.S. market." "Quest Diagnostics provides the best possible combination of health care expertise, geographic reach, and patient service infrastructure to support U.S. commercialization and revenue growth," said David Elsley, President and Chief Executive Officer of Vasogen.